What is HC Wainwright’s Forecast for RVPH Q2 Earnings?

Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) – Analysts at HC Wainwright issued their Q2 2026 earnings estimates for shares of Reviva Pharmaceuticals in a report released on Monday, October 27th. HC Wainwright analyst R. Selvaraju forecasts that the company will post earnings per share of ($0.08) for the quarter. HC Wainwright currently has a “Buy” rating and a $4.00 price objective on the stock. The consensus estimate for Reviva Pharmaceuticals’ current full-year earnings is ($0.97) per share.

A number of other equities analysts have also weighed in on the stock. Weiss Ratings reiterated a “sell (e+)” rating on shares of Reviva Pharmaceuticals in a report on Wednesday, October 8th. D. Boral Capital reiterated a “buy” rating and issued a $2.00 price target on shares of Reviva Pharmaceuticals in a report on Tuesday. Maxim Group reduced their target price on shares of Reviva Pharmaceuticals from $5.00 to $2.00 and set a “buy” rating on the stock in a report on Friday, August 15th. Benchmark reduced their target price on shares of Reviva Pharmaceuticals from $14.00 to $7.00 and set a “speculative buy” rating on the stock in a report on Monday, September 15th. Finally, Wall Street Zen upgraded shares of Reviva Pharmaceuticals to a “sell” rating in a report on Saturday, October 4th. Eight research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $3.86.

Reviva Pharmaceuticals Stock Down 2.4%

Shares of RVPH opened at $0.58 on Tuesday. The firm has a market cap of $40.03 million, a PE ratio of -0.89 and a beta of -0.08. The company’s fifty day moving average is $0.49 and its two-hundred day moving average is $0.60. Reviva Pharmaceuticals has a fifty-two week low of $0.25 and a fifty-two week high of $4.28.

Reviva Pharmaceuticals (NASDAQ:RVPH) last announced its quarterly earnings results on Thursday, August 14th. The company reported ($0.12) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.15) by $0.03.

Hedge Funds Weigh In On Reviva Pharmaceuticals

A number of institutional investors have recently added to or reduced their stakes in the company. Geode Capital Management LLC lifted its holdings in Reviva Pharmaceuticals by 6.9% in the 2nd quarter. Geode Capital Management LLC now owns 448,202 shares of the company’s stock worth $171,000 after buying an additional 29,063 shares in the last quarter. BluePointe Capital Management LLC lifted its holdings in Reviva Pharmaceuticals by 354.7% in the 1st quarter. BluePointe Capital Management LLC now owns 47,185 shares of the company’s stock worth $45,000 after buying an additional 36,807 shares in the last quarter. NewEdge Advisors LLC acquired a new position in Reviva Pharmaceuticals in the 1st quarter worth $58,000. XTX Topco Ltd acquired a new position in Reviva Pharmaceuticals in the 2nd quarter worth $31,000. Finally, Private Advisor Group LLC acquired a new position in Reviva Pharmaceuticals in the 1st quarter worth $191,000. Institutional investors and hedge funds own 63.18% of the company’s stock.

About Reviva Pharmaceuticals

Reviva Pharmaceuticals Holdings, Inc, a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company's lead product candidate comprises brilaroxazine (RP5063) for the treatment of various neuropsychiatric indications, including schizophrenia, bipolar disorder, major depressive disorder, attentiondeficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia and Alzheimer's disease, and Parkinson's disease psychosis; in clinical development respiratory indications, such as pulmonary arterial hypertension and idiopathic pulmonary fibrosis; and in preclinical development for the treatment of psoriasis.